TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

Background When carcinoid syndrome (CS) diarrhea (CSD) is inadequately controlled with long‐acting somatostatin analogs (SSAs), clinical practice guidelines recommend addition of the tryptophan hydroxylase inhibitor telotristat ethyl (TE). In a 12‐week multinational, randomized controlled trial, TE...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2019-11, Vol.24 (11), p.1446-1452
Hauptverfasser:	Strosberg, Jonathan, Joish, Vijay N., Giacalone, Susan, Perez‐Olle, Raul, Fish‐Steagall, Ann, Kapoor, Kanika, Dharba, Sam, Lapuerta, Pablo, Benson, Al B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoid tumor Endocrinology Lanreotide Malignant carcinoid syndrome Neuroendocrine tumors Octreotide Telotristat ethyl
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!